Research programme: neurodegenerative disorder therapeutics - Cypralis/Janssen Pharmaceuticals
Latest Information Update: 21 Sep 2016
At a glance
- Originator Cypralis Limited; Janssen Pharmaceuticals
- Developer Cypralis Limited; Janssen Pharmaceuticals; Selcia
- Class Small molecules
- Mechanism of Action Cyclophilin D inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders